Member Info for Matador78

I didn't want to bother you with the Thursday news. I know some people aren't too keen.

https://www.businesswire.com/news/home/20191031005173/en/Intensity-Therapeutics-Treats-Patient-Combination-INT230-6-Merck%E2%80%99s

The first part of the combination cohort of IT-01 expects to enroll approximately six patients with different types of advanced solid tumors in order to test safety of the combination. The second part will evaluate the safety and efficacy of the combination in several Phase 2 cohorts of patients with different types of cancer, including cancers that are not immunogenic.

“Bringing INT230-6 into human testing in combination with Keytruda is a major milestone for Intensity Therapeutics,” commented Lewis H. Bender, President and Chief Executive Officer of Intensity Therapeutics. “Our preclinical and clinical data to date have already demonstrated good safety for INT230-6 as a single agent, with evidence of patient benefit and immune activation in highly refractory cancer patients. We believe the immune activation potential of INT230-6 can be increased when combined with Keytruda, and are excited to have initiated human testing of the combination.”

You smell better when you're asleep : )

Carl is also advising another BIG announcement soon from Factom.

It's probably going to be worthwhile buying and holding your tickets now guys.

This could be it.

https://www.coindesk.com/uk-banking-pilot-aims-to-streamline-compliance-using-factom-blockchain?utm_source=twitter&utm_medium=coindesk&utm_term=&utm_content=&utm_campaign=Organic%20

Good points Doggo

Good points Rich.

The way things are going I don't think the market has any confidence in them anyway Rich.

We need the six million back from Factom and whatever we get for Leap.

Either wrap it up or put it into EMMAC and Juve

I don't see it as such a bad idea to reward shareholders with a payout in the short term.

It would fill in a shortfall in performance since Nuuvera if nothing else. I'd be more inclined to buy if I knew there was kickbacks.

If only it was a Thursday : (

It's a good plan Rich but it's looking like the sub 6's are about to be taken off the table for the time being. There's a few guys who were planning on topping up this week after selling off elsewhere.

I keep thinking theyre going to dip it dramatically to trigger some stops.

I assume so Midas.

Youre absolutely right. Sell up and buy IRR youll make a mint.

https://www.businesswire.com/news/home/20191030005329/en/AgeX-Therapeutics-Juvenescence-Publish-Paper-Engineering-Strategies

intensity therapeutics took about 3 months to rns after their poster presentation to tell people they were collaborating with Merck.

These things take time guys. Hold your shares and try to switch off

Last Orders!

Not for long. : )

It's all fake O'Donnell sell up tomorrow and buy IRR.

There only 5 people that buy ffwf anyway and three of them have sold now so. Just buy IRR and when that goes to 18 pence sell it and well all start ramping FFWD again.

Simple.

Yeah you guys are right.

Sell up and buy IRR everyone else has.

https://www.businesswire.com/news/home/20191022005295/en/Intensity-Therapeutics%E2%80%99-Intratumoral-INT230-6-Tumor-Regression-Immune

WESTPORT, Conn.--(BUSINESS WIRE)--Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary intratumoral immunotherapy products to kill tumors and increase immune system recognition of solid cancers, today announced that data from the ongoing clinical trial of its lead product candidate INT230-6 was selected for a podium presentation at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting, taking place November 6-10, 2019, in National Harbor, MD.

Details of the oral presentation are as follows:

Title: Intratumoral INT230-6 injection into solid tumors kills tumors and induces immune cell infiltration leading to abscopal responses and prolonged disease control in multiple refractory cancer types
Abstract Number: O31
Date/Time: Saturday, November 9, 2019, 3:45-4:00 p.m. ET
Session: Concurrent Session 309: Single Agent Phase 1 Clinical Trials
Location: Prince George's Exhibition Hall C
Presenter: Jacob Thomas, MD, Assistant Professor of Clinical Medicine, University of Southern California

https://www.paymentssource.com/news/to-push-crypto-payments-factoms-pegnet-creates-tokens-for-many-currencies